Most recent by Ashley Killen
Machine learning helps improve end-of-life care, communication for people with cancer
A machine learning algorithm that triggered electronic reminders to health care providers increased the rate at which providers and patients spoke about end-of-life care preferences, according to randomized trial results.
Review of meeting abstracts shows toxicity reporting inconsistent, incomplete
Toxicity reporting in certain abstracts presented in recent years at ASH Annual Meeting and Exposition appeared inconsistent and incomplete, according to a systematic review.
Inflammation levels linked to survival in acute myeloid leukemia
Severe inflammation among individuals with acute myeloid leukemia limits their bodies’ ability to kill cancerous blood cells, according to study results.
World Cancer Day: Oncology leaders share practical advice to ‘close the care gap’
World Cancer Day will be observed Feb. 4.
Artificial intelligence tool may help predict lung cancer risk regardless of smoking history
An artificial intelligence tool predicted a person’s lung cancer risk after analyzing a single low-dose CT scan, according to study results.
Race linked to survival disparities in head and neck cancer trials
Black patients in head and neck cancer clinical trials consistently achieved poorer survival than white patients who received the same treatments, according to study results.
Brentuximab vedotin-nivolumab regimen induces response in limited-stage Hodgkin lymphoma
NEW ORLEANS — Induction with brentuximab vedotin plus AVD chemotherapy followed by nivolumab consolidation exhibited encouraging activity among previously untreated patients with limited-stage non-bulky Hodgkin lymphoma, according to study results.
Modakafusp alfa exhibits ‘clear evidence of activity’ in advanced multiple myeloma
NEW ORLEANS — Modakafusp alfa exhibited encouraging activity as treatment for relapsed or refractory multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
Efficacy, safety data support use of lisocabtagene maraleucel at community sites
NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.
Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL
NEW ORLEANS — Cumulative anesthesia exposure appeared associated with impairments in neurocognitive function among children with high-risk acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.